- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03031262
Efficacy and Safety of Chidamide in CBF Leukemia
Study Overview
Detailed Description
In this open-label, randomized, prospective clinical trial, CBF AML(including AML1-ETO or CBF-MYH11 mutated patients) patients who have reached CR are randomised into two groups and receive HDAC or high dose of cytarabine plus chidamide.
In experimental group, patients receive cytarabine at a dose of 3g/㎡/d on the first, third and fifth day and chidamide at a dose of 20mg/d twice a week for 3 months.Patients in control group only receive cytarabine at the same dose.
The safety and efficacy of chidamide is evaluated. The primary outcome is relapse-free survival rate after treatment.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Tianjin
-
Tianjin, Tianjin, China
- Recruiting
- Institute of Hematology & Blood Diseases Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age of 14 to 55 years old;
- Patients that meet the diagnostic criteria(WHO 2008 criteria) of AML (except APL subtypes) and with AML1-ETO or CBF-MYH11 mutation.
- Reached CR after induction regimen.
- ECOG score of ≤ 2;
- Patients with eligible laboratory examination including liver,renal and heart function.
- Adult patients are willing to participate in the study and sign the informed consent by themselves or by their immediate family. Patients under 18 years old willing to participate should have their legal guardians sign the informed consent.
Exclusion Criteria:
- Secondary leukemia.
- Patients had other tumor at active stage or had received radiotherapy or chemotherapy in the last 6 months due to other tumor.
- Patients with other blood diseases(for example, haemophiliacs) are excluded.However, patients with abnormal blood count, but with undiagnosed MDS or MPD patients are included.
- Acute panmyelosis with myelofibrosis and myeloid sarcoma patients;
- With BCR-ABL fusion gene;
- Pregnant or lactating women;
- With ineligible renal or liver function;
- With active cardiovascular disease;
- Severe infection disease including uncured tuberculosis pulmonary aspergillosis;
- AIDS;
- Patients had central nervous system involvement when they were diagnosed as AML.
- Patients with epilepsy or dementia or other mental disease who couldn't understand or follow the research.
- Drugs, medical, mental or social situation may distract patients from following the research or being evaluated the results.
- Patients with other factors which were considered unsuitable to participate in the study by the investigators.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: High Dose of Cytarabine
CBF Patients who reach CR after reduction therapy receive high dose of cytarabine.
|
Cytarabine at a dose of 3g/㎡/d on the first, third and fifth day.
Other Names:
|
EXPERIMENTAL: HDAC + Chidamide
CBF Patients who reach CR after reduction therapy receive high dose of cytarabine plus chidamide.
|
Cytarabine at a dose of 3g/㎡/d on the first, third and fifth day.
Other Names:
Chidamide at a dose of 20mg/d twice a week for 3 months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relapse-Free Survival Rate (RFS)
Time Frame: Within 5 years after randomization
|
RFS is defined as the time from the date of complete remission (CR) after entry in this trial until the date of documented relapse or death for CBF positive leukemia patients who achieve CR.
|
Within 5 years after randomization
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Non-relapse Mortality
Time Frame: through treatment completion, an average of 5 months
|
through treatment completion, an average of 5 months
|
Overall Survival Rate (OS)
Time Frame: Within 5 years after randomization
|
Within 5 years after randomization
|
Cumulative incidence of relapse
Time Frame: Within 5 years after randomization
|
Within 5 years after randomization
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IIT2016007-EC-1-3
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on AML
-
H Scott BoswellTakedaTerminatedAML | AML, AdultUnited States
-
Technische Universität DresdenAbbVieActive, not recruitingRelapsed Adult AML | Refractory AMLGermany
-
Carbiogene Therapeutics Co. Ltd.Zhejiang Provincial People's HospitalRecruiting
-
National Research Center for Hematology, RussiaFederal Research Clinical Center of Federal Medical & Biological Agency,... and other collaboratorsRecruiting
-
Glycostem Therapeutics BVRecruiting
-
Etan OrgelAstellas Pharma Global Development, Inc.No longer available
-
Chinese PLA General HospitalNavy General Hospital, BeijingCompleted
-
University Hospital Inselspital, BerneWithdrawn
-
Turkish Leukemia Study GroupCompleted
Clinical Trials on Cytarabine
-
Sunesis PharmaceuticalsCompletedAcute Myeloid LeukemiaUnited States, Canada, Spain, Belgium, Korea, Republic of, Australia, France, Germany, Poland, New Zealand, United Kingdom, Czechia, Austria, Hungary, Italy
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Chronic Myelomonocytic Leukemia | Refractory Chronic Myelomonocytic Leukemia | Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome | Blasts 10-19 Percent of Bone Marrow Nucleated Cells and other conditionsUnited States
-
Jianxiang WangUnknownAcute Myeloid LeukemiaChina
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)RecruitingRefractory Acute Myeloid Leukemia | Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | Persistent DiseaseUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAcute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid LeukemiaUnited States
-
Roswell Park Cancer InstituteJazz PharmaceuticalsRecruitingAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Acute Myeloid Leukemia With Myelodysplasia-Related ChangesUnited States
-
M.D. Anderson Cancer CenterRecruitingRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
M.D. Anderson Cancer CenterRecruitingMyelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myeloproliferative Neoplasm | Acute Myeloid Leukemia With Gene MutationsUnited States
-
Institute of Hematology & Blood Diseases Hospital...Recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Blasts More Than 10 Percent of Bone Marrow Nucleated CellsUnited States